Presenting about HARMONY MDS and AML research at EBMT2024

We participated in the 50th annual meeting of EBMT, the European Society for Blood and Marrow Transplantation. EBMT2024 took place in Glasgow, United Kingdom, from 14 to 17 April 2024.

Highlight of the congress for us, was the joint EMBT-HARMONY session (JS07) on 17 April where we could provide insicht in running projects and interact with participants about the opportunities working with big data can offer bone marrow transplant professionals. The theme of the session was harnessing data-innovation for better outcomes. Apart from lectures, the session program included a round table discussion about sharing data and joint research opportunities in MDS and AML.

Presenters were

Anna Sureda, EBMT President, about EBMT’s view on sharing data and data-driven research to offer new opportunities for bone marrow transplant professionals

Valeria Santini, University of Florence, HARMONY Alliance, EHA SWG on Myelodysplastic Syndromes (MDS) Executive Board about Data-innovation in MDS: Converting data into insights

Carmelo Gurnari, University of Rome Tor Vergata, Vice-chair MDS subcommittee EBMT-CMWP (Chronic Malignancies Working Party) about Data-innovation in MDS: Transplant vs. non-transplant strategies in MDS: a joint EBMT-HARMONY study

Lars Bullinger, Charité – Universitätsmedizin Berlin, HARMONY Alliance, EHA SWG for Acute Myeloid Leukemia (AML) about Data-innovation in AML - The HARMONY AML risk of relapse tool to guide alloHSCT decision-making

The round table panel consisted of

Donal McLornan, Chair EBMT-CMWP (Chronic Malignancies Working Party)

Fabio Ciceri, Chair EBMT-ALWP (Acute Leukemia Working Party)

Valeria Santini, University of Florence, HARMONY Alliance, EHA SWG on Myelodysplastic Syndromes (MDS) Executive Board

Carmelo Gurnari, University of Rome Tor Vergata, Vice-chair MDS subcommittee EBMT-CMWP

Lars Bullinger, Charité – Universitätsmedizin Berlin, HARMONY Alliance, EHA SWG for Acute Myeloid Leukemia (AML)

Anna Sureda, EBMT President (session chair)

The HARMONY Alliance would like to thank EBMT for this opportunity.

Receive the latest news. Click here to subscribe!

Public-private partnership for Big Data in Hematology

HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).